
    
      The objectives of the study is to evaluate the efficacy, safety, and dose of DS-8500a
      compared with placebo in patients with type 2 diabetes mellitus after a 12-week oral
      administration of DS-8500a at 25, 50, or 75 mg in a double-blind, parallel-group comparison
      study. In addition, the clinical positioning of DS-8500a relative to an existing drug will be
      investigated using sitagliptin as a comparator.
    
  